Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...
Medical Device Network on MSN1d
Globus Medical strengthens SCS market position with $250m Nevro dealGlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback